Search

Your search keyword '"William W. Lamph"' showing total 56 results

Search Constraints

Start Over You searched for: Author "William W. Lamph" Remove constraint Author: "William W. Lamph"
56 results on '"William W. Lamph"'

Search Results

1. Data from Identification of Biomarkers Modulated by the Rexinoid LGD1069 (Bexarotene) in Human Breast Cells Using Oligonucleotide Arrays

2. Supplementary Diagrams 1-2 from Identification of Biomarkers Modulated by the Rexinoid LGD1069 (Bexarotene) in Human Breast Cells Using Oligonucleotide Arrays

3. Supplementary Figures 3-5 from Identification of Biomarkers Modulated by the Rexinoid LGD1069 (Bexarotene) in Human Breast Cells Using Oligonucleotide Arrays

4. Supplementary Tables 1-4, Figures 1-2 from Identification of Biomarkers Modulated by the Rexinoid LGD1069 (Bexarotene) in Human Breast Cells Using Oligonucleotide Arrays

5. Repression of exogenous gene expression by the retinoic acid target gene G0S2

6. The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice

7. The Rexinoid LG100268 Prevents the Development of Preinvasive and Invasive Estrogen Receptor–Negative Tumors in MMTV-erbB2 Mice

8. Synthesis and Characterization of Nonsteroidal Glucocorticoid Receptor Modulators for Multiple Myeloma

9. Identification of Biomarkers Modulated by the Rexinoid LGD1069 (Bexarotene) in Human Breast Cells Using Oligonucleotide Arrays

10. The Combination of the Rexinoid, LG100268, and a Selective Estrogen Receptor Modulator, Either Arzoxifene or Acolbifene, Synergizes in the Prevention and Treatment of Mammary Tumors in an Estrogen Receptor–Negative Model of Breast Cancer

11. Differentiation and growth inhibition mediated via the RXR:PPARγ heterodimer in colon cancer

12. A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer

13. The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma

14. The Retinoid X Receptor-Selective Retinoid, LGD1069, Down-regulates Cyclooxygenase-2 Expression in Human Breast Cells through Transcription Factor Crosstalk: Implications for Molecular-Based Chemoprevention

15. Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma

16. The Selective Estrogen Receptor Modulator Arzoxifene and the Rexinoid LG100268 Cooperate to Promote Transforming Growth Factor β-Dependent Apoptosis in Breast Cancer

17. Arsenic Trioxide as an Inducer of Apoptosis and Loss of PML/RARα Protein in Acute Promyelocytic Leukemia Cells

18. Induction of Apoptosis Without Differentiation by Retinoic Acid in PLB-985 Cells Requires the Activation of Both RAR and RXR

19. A Retinoid-Resistant Acute Promyelocytic Leukemia Subclone Expresses a Dominant Negative PML-RARα Mutation

20. The efficacy of 9-cis retinoic acid in experimental models of cancer

21. Discovery of Novel Retinoic Acid Receptor Agonists Having Potent Antiproliferative Activity in Cervical Cancer Cells

22. Identification of a nuclear receptor that is activated by farnesol metabolites

23. The rexinoid bexarotene represses cyclin D1 transcription by inducing the DEC2 transcriptional repressor

24. G0S2 is an all-trans-retinoic acid target gene

25. Prevention and Treatment of Experimental Estrogen Receptor–Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268

26. The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis

27. Rexinoid-induced Expression of IGFBP-6 Requires RAR?-dependent Permissive Cooperation of Retinoid Receptors and AP-1

28. Negative and positive regulation by transcription factor cAMP response element-binding protein is modulated by phosphorylation

29. Fos-Jun Conspiracy: Implications for the Cell

30. Receptor-selective retinoids inhibit the growth of normal and malignant breast cells by inducing G1 cell cycle blockade

31. The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells

32. A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer

33. Responsiveness to the retinoic acid receptor-selective retinoid LGD1550 correlates with abrogation of transforming growth factor alpha/epidermal growth factor receptor autocrine signaling in head and neck squamous carcinoma cells

34. Retinoic acid receptor ligands based on the 6-cyclopropyl-2,4-hexadienoic acid

35. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice

36. Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268

37. Activation of retinoid X receptors induces apoptosis in HL-60 cell lines

38. Platelet derived growth factor (PDGF), androgens and inflammation: possible etiologic factors in the development of prostatic hyperplasia

39. G0S2 is an all-trans-retinoic acid target gene

40. 66 The combination of taxol and a selective retinoid X-receptor ligand targretin® (LGD1069) prevents and overcomes acquired taxol resistance in breast carcinoma

41. Effect of the Retinoid X Receptor-Selective Ligand LGD1069 on Mammary Carcinoma After Tamoxifen Failure

43. Synergistic effect of a retinoid X receptor-selective ligand bexarotene (LGD1069, Targretin) and paclitaxel (Taxol) in mammary carcinoma.

44. Transformation-Defective Virus Generation from Cloned Nondefective Avian Sarcoma Virus

45. fos andjun interaction: The role of the leucine zipper

46. Loss of viral gene expression and retention of tumorigenicity by Abelson lymphoma cells

47. Different genes control the susceptibility of mice to Moloney or Abelson murine leukemia viruses

48. Induction of proto-oncogene JUN/AP-1 by serum and TPA

49. Monoclonal Antibody to Abelson Lymphoma Cells

50. Direct interaction between fos and jun nuclear oncoproteins: role of the 'leucine zipper' domain

Catalog

Books, media, physical & digital resources